Globus Medical to acquire NuVasive in all-stock merger; each NuVasive share gets 0.75 GMED share

GLOBUS MEDICAL INC

Each NuVasive share converted into 0.75 Globus Medical Class A common shares; no cash consideration except fractional shares.
Expected close by Oct 8, 2023, extendable to Feb 8, 2024; subject to HSR, shareholder approvals, and other conditions.
Termination fees: NuVasive pays $120M (reduced to $75M in Specified Period); Globus pays $120M in certain scenarios.
Globus board expanded to 11 members; 3 NuVasive directors to be appointed post-close.
David & Sonali Paul (70% voting power) agree to vote Globus Class B shares in favor of issuance.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GLOBUS MEDICAL INC entered into Agreement and Plan of Merger with NuVasive, Inc. (effective 2023-02-08).

Action: entry
Agreement: merger
Counterparty: NuVasive, Inc.
Effective: 2023-02-08

Exact text from the filing

On February 8, 2023, NuVasive, Inc., a Delaware corporation (“NuVasive”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Globus Medical, Inc., a Delaware corporation (“Globus Medical”) and Zebra Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Globus Medical (“Merger Sub”).

View on SEC.gov

Browse all material agreements →

GLOBUS MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-23-030375

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.